Table 3.
Distribution of Cases by Clinicopathological Evaluation
| Variable | Control–low path | Control–AD path | Control-LBD | AD dementia | DLB/PDD | Total |
|---|---|---|---|---|---|---|
| Cases, n | 7 | 10 | 2 | 16 | 5 | 40 |
| Last CASI score (means ± SD) | 94 ± 3 | 90 ± 5 | 95 and 93 | Not applicable | Not applicable | Not applicable |
| AD path | 7 Low, 0 inter., 0 high | 0 Low, 4 inter., 6 high | 1 Low, 1 inter., 0 high | 0 Low, 1 inter., 15 high | 0 Low, 2 inter., 3 high | 8 Low, 8 inter., 24 high |
| MVL ≥3 | 0 | 1 | 0 | 4 | 0 | 5 |
| LBD (any) | 0 | 0 | 2 | 0 | 5 | 7 |
| APOE4 alleles, n | 0 of 14 | 2 of 20 | 0 of 4 | 8 of 28∗ | 2 of 10 | 12 of 76 |
AD, Alzheimer disease; CASI, Cognitive Assessment Screening Instrument; DLB, dementia with Lewy bodies; inter., intermediate; LBD, Lewy body disease; MVL, microvascular lesion; path, pathological change; PDD, Parkinson disease dementia.
∗
APOE genotype was not available for two participants.